Cell Culture Engineering. 1st ed. 2006

種類:

電子ブック

責任表示:

edited by Wei-Shu Hu

出版情報:

Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2006

著者名:

• Hu, Wei-Shu.
• SpringerLink (Online service)

シリーズ名:

Advances in Biochemical Engineering/Biotechnology ; 101

ISBN:

9783540340072 [3540340076]    

注記:

Established Bioprocesses for Producing Antibodies as a Basis for Future Planning -- Fedbatch Culture and Dynamic Nutrient Feeding -- The “Push-to-Low” Approach for Optimization of High-Density Perfusion Cultures of Animal Cells -- Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture -- Engineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals.
Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent

ローカル注記:

学内専用E-BOOKS (local access only)